Inferra AI / Company / FMC
FMC Corp
FMC · Materials
Last earnings Oct 29, 2026
Key results
Revenuequarter
$867 million
Revenue of $867 million, down 17 percent versus Q2 2025 Revenue excluding India 1 of $841 million, down 20 percent versus Q2 2025 (which included India) Organic revenue 2 for the period declined 22 percent Consolidated GAAP net loss of $187 million
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
Growthquarter
down 17 percent
revenue of $867 million, down 17 percent versus second quarter 2025.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
Second quarter 2026 revenue, excluding India, was $841 million, down 20 percent versus second quarter 2025, which included India.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
FMC Revenue Q2 2026 Total Revenue Change (GAAP) (17)% Total Revenue Change (ex-India) (Non-GAAP) (20)% Less 2025 revenue for India held for sale business (5)% Like-for-Like Revenue Change (Non-GAAP) (15)% Second quarter sales of $841 million, excluding India, were 20 percent lower than prior year.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
Free cash flowquarter
$357 million
Free cash flow was $357 million, an improvement of $318 million versus Q2 2025 primarily due to higher cash from operations.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
2025 Total revenue (GAAP) change (17) % (12) % Less Revenue for India held for sale business for the three and six months ended June 30, 2026 3 % 1 % Revenue excluding India (non-GAAP) change (1) (20) % (13) % Less Foreign currency impact 2 % 3 % Organic revenue (non-GAAP) change (2) (22) % (16) % ___________________ (1) Beginning with the third quarter of 2025, revenue from the India commercial business is excluded from our adjusted results during the held for sale period for non-GAAP purposes.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
AI analysis
Q2 2026 · reported Jul 29, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Jul 29, 2026 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q2 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $867 million | $542 million | — |
| Growth | down 17 percent | down 49 percent | — |
| Free cash flow | $357 million | $233 million | — |
Guidance · company-stated
“is expected to be $620 million to $680 million”
“is expected to be $1.19 to $1.49”
“is expected to be $75 million to $225 million”
“is forecasted to be in the range of $275 million to $315 million”
“$620 million to $680 million”
“$1.19 to $1.49”
Guidance stated in the release for Full year 2026; figures as stated.
Cash flow & capex
Capital allocation
Strategy Update FMC continued to make progress on its four operational pillars during the second quarter reducing debt, improving the competitiveness of its core portfolio, managing the post-patent transition for Rynaxypyr and accelerating growth of new active ingredients.
During the quarter, FMC announced the key components of its targeted approximately $1 billion of proceeds to be used for debt reduction.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +303.7% computed from stated figures
Event summary
Second quarter adjusted earnings per diluted share of $0.26 was down 62 percent versus second quarter 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
revenue: “revenue guidance 1 is now $3.50 billion to $3.70 billion”
Adjusted EBITDA: “Adjusted EBITDA is expected to be $620 million to $680 million”
Adjusted EPS: “Adjusted EPS is expected to be $1.19 to $1.49”
Free cash flow: “Free cash flow is expected to be $75 million to $225 million”
Adjusted EBITDA: “Adjusted EBITDA is forecasted to be in the range of $275 million to $315 million”
Adjusted EBITDA: “Adjusted EBITDA $620 million to $680 million”
Adjusted EPS: “Adjusted EPS $1.19 to $1.49”
revenue (“Full year 2026”)
“Full year 2026 revenue guidance 1 is now $3.50 billion to $3.70 billion, a decline of 7 percent at the midpoint versus prior year 1 .”
Adjusted EBITDA (“Full year 2026”)
“Adjusted EBITDA is expected to be $620 million to $680 million, a decline of 23 percent versus prior year, as lower price and an FX headwind are partially offset by favorable costs.”
Adjusted EPS (“Full year 2026”)
“Adjusted EPS is expected to be $1.19 to $1.49, a decrease of 55 percent versus prior year, primarily due to lower Adjusted EBITDA and increased interest expense.”
Free cash flow (“Full year 2026”)
“Free cash flow is expected to be $75 million to $225 million.”
Adjusted EBITDA (“fourth quarter 2025”)
“Adjusted EBITDA is forecasted to be in the range of $275 million to $315 million, an increase of 5 percent at the midpoint versus the prior year as lower price and an FX headwind are more than offset by higher volume and favorable costs.”
Adjusted EBITDA (“Full-Year 2026”)
“2025* (7)% (2)% (9)% 4% Adjusted EBITDA $620 million to $680 million $395 million to $455 million $120 million to $140 million $275 million to $315 million Growth at midpoint vs.”
Adjusted EPS (“Full-Year 2026”)
“2025* (23)% (18)% (45)% 5% Adjusted EPS $1.19 to $1.49 $1.16 to $1.46 $0.05 to $0.13 $1.09 to $1.33 Growth at midpoint vs.”
Guidance stated in the release for Full year 2026; figures as stated.
Capital allocation
Strategy Update FMC continued to make progress on its four operational pillars during the second quarter reducing debt, improving the competitiveness of its core portfolio, managing the post-patent transition for Rynaxypyr and accelerating growth of new active ingredients.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
During the quarter, FMC announced the key components of its targeted approximately $1 billion of proceeds to be used for debt reduction.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
With these actions and other minor asset sales to be completed this year, FMC expects to generate approximately $1 billion of proceeds to be used for debt paydown.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
In May 2026, the Company announced that it has signed a definitive agreement to sell the India commercial business to Crystal Crop Protection Limited for consideration of $252 million, subject to customary adjustments for cash, debt and working capital.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
We believe that this non-GAAP financial measure provides a useful basis for investors and securities analysts to evaluate the cash generated by routine business operations, including to assess our ability to repay debt, fund acquisitions and return capital to shareholders through share repurchases and dividends.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
(4) Includes the make-whole premium paid in connection with the early redemption of certain debt instruments during the six months ended June 30, 2025.
SEC original ↗FMC Corp — 10-Q Quarterly report10-QJul 30, 2026
Strategy & priorities
During the quarter, we completed several important actions that strengthened FMC's financial foundation and provide greater flexibility to execute our strategy, said Pierre Brondeau, chairman, chief executive officer and president.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
With the strategic review now concluded, we have clarity on the path forward and remain focused on improving competitiveness, advancing our technology portfolio and positioning the company for long-term growth.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
Strategy Update FMC continued to make progress on its four operational pillars during the second quarter reducing debt, improving the competitiveness of its core portfolio, managing the post-patent transition for Rynaxypyr and accelerating growth of new active ingredients.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
With these actions in place, the FMC Board of Directors has concluded the exploration of strategic options announced in February 2026.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
The company remains focused on executing its operational priorities and strengthening the foundation for future growth through its differentiated technology portfolio.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
Risks & headwinds
The removal of India represented a 5 percent sales headwind.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
India represents a 2 percent headwind 1 .
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
Adjusted EBITDA is expected to be $620 million to $680 million, a decline of 23 percent versus prior year, as lower price and an FX headwind are partially offset by favorable costs.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
Adjusted EBITDA is forecasted to be in the range of $120 million to $140 million, a decrease of 45 percent at the midpoint versus the prior year as lower sales and an FX headwind are partially offset by favorable costs.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
Adjusted EBITDA is forecasted to be in the range of $275 million to $315 million, an increase of 5 percent at the midpoint versus the prior year as lower price and an FX headwind are more than offset by higher volume and favorable costs.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
FMC's innovative crop protection solutions including biologicals, crop nutrition, digital and precision agriculture enable growers and crop advisers to address their toughest challenges economically while protecting the environment.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
What changed vs prior quarter
Revenue — prior quarter passage and this quarter's passage are both cited.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
Growth — prior quarter passage and this quarter's passage are both cited.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
Free cash flow — prior quarter passage and this quarter's passage are both cited.
SEC original ↗FMC Corp — Earnings release (8-K exhibit)EX-99Jul 29, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documents- Q3 2026
- 8-KFMC
Oct 29, 2026
- 8-KFMC
Oct 21, 2026
- 8-KFMC
Oct 21, 2026
- 8-KFMC
Oct 15, 2026
- Q2 2026
- 8-KFMC
Sep 23, 2026
- 10-QFMC
Jul 30, 2026
- 8-KFMC
Jul 29, 2026
- 8-KFMC
Jul 1, 2026
- Q1 2026
- 8-KFMC
Jun 23, 2026
- 8-KFMC
Jun 23, 2026
- 8-KFMC
Jun 5, 2026
- 8-KFMC
May 21, 2026
- 8-KFMC
May 19, 2026
- 10-QFMC
Apr 30, 2026
- 8-KFMC
Apr 29, 2026
- 8-KFMC
Apr 29, 2026
- 8-KFMC
Apr 20, 2026
- Q4 2025
- 10-KFMC
Feb 27, 2026
- 8-KFMC
Feb 4, 2026
- Q3 2025
- 8-KFMC
Dec 12, 2025
- 8-KFMC
Dec 9, 2025
- 8-KFMC
Dec 3, 2025
- 10-QFMC
Oct 30, 2025
- 8-KFMC
Oct 29, 2025
- 8-KFMC
Oct 29, 2025
- Q2 2025
- 10-QFMC
Jul 31, 2025
- 8-KFMC
Jul 30, 2025
- Q1 2025
- 8-KFMC
May 28, 2025
- 8-KFMC
May 21, 2025
- 10-QFMC
May 1, 2025
- 8-KFMC
Apr 30, 2025
Earnings releases
9 documentsPresentations
0 documentsNo presentations for FMC Corp are held in this edition of the library.
Transcripts
0 documentsNo transcripts for FMC Corp are held in this edition of the library.
Mentioned by
9 companiesOther tracked companies whose held documents mention FMC Corp by name or ticker. A mention is counted once per document, from the document text the library holds.
“… plc $ 224.7 $ 274.6 $ 53.0 $ 842.9 $ 56.2 Earnings per share attributable to TechnipFMC plc Basic $ 0.53 $ 0.64 $ 0.12 $ 1.96 $ 0.13 Diluted $ 0.52 $ 0.63 $ 0.12 $ 1.91 $ 0.12 Weighted average… … • Subsea inbound of $2.7 billion in the ”
American Healthcare Reit, Inc. (AHR)
“dditional costs or risks from increasing scrutiny and expectations regarding… … to TechnipFMC plc $ 142.0 $ 224.7 $ 157.1 Earnings per share attributable to TechnipFMC plc Basic $ 0.34 $ 0.53 $ 0.36 Diluted $ 0.33 $ 0.52 $ 0.35 Weighted a”
“plc $ 309.7 $ 269.5 $ 274.6 $ 721.2 $ 618.2 Earnings per share attributable to TechnipFMC plc Basic $ 0.76 $ 0.65 $ 0.64 $ 1.74 $ 1.44 Diluted $ 0.75 $ 0.64 $ 0.63 $ 1.71 $ 1.40 Weighted average… …per share $0.75 $0.68 $0.64 10.3% 17.2% ”
“plc $ 269.5 $ 142.0 $ 186.5 $ 411.5 $ 343.6 Earnings per share attributable to TechnipFMC plc Basic $ 0.65 $ 0.34 $ 0.43 $ 0.98 $ 0.80 Diluted $ 0.64 $ 0.33 $ 0.42 $ 0.97 $ 0.78 Weighted average… …Company inbound orders of $2.8 billion; S”
“plc $ 362.7 $ 260.5 $ 269.5 $ 623.2 $ 411.5 Earnings per share attributable to TechnipFMC plc Basic $ 0.92 $ 0.65 $ 0.65 $ 1.57 $ 0.98 Diluted $ 0.90 $ 0.64 $ 0.64 $ 1.53 $ 0.97 Weighted average… …per share $0.91 $0.64 $0.68 42.2% 33.8% ”
“ta science; risks of pirates and maritime conflicts endangering our maritime… … to TechnipFMC plc $ 260.5 $ 242.7 $ 142.0 Earnings per share attributable to TechnipFMC plc Basic $ 0.65 $ 0.60 $ 0.34 Diluted $ 0.64 $ 0.59 $ 0.33 Weighted a”
“plc $ 242.7 $ 309.7 $ 224.7 $ 963.9 $ 842.9 Earnings per share attributable to TechnipFMC plc Basic $ 0.60 $ 0.76 $ 0.53 $ 2.34 $ 1.96 Diluted $ 0.59 $ 0.75 $ 0.52 $ 2.30 $ 1.91 Weighted average… …$0.70 $0.75 $0.54 (6.7%) 29.6% Inboun”
Liberty Latin America Ltd. (LILA)
“ed strength in residential mobile, with subscription revenue growing 8%, driven by rising FMC penetration and strong postpaid subscriber additions, as well…”
“ependence on the continuing services… …Oilwell Varco, Oil States International and TechnipFMC. ChampionX data represents legacy Apergy prior to merger. TechnipFMC financial data represents FMC Technologies from 2015-2016 and TechnipFMC pro forma for ”
See also the earnings calendar for every tracked company’s next earnings date.